[go: up one dir, main page]

NO20055774L - Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere - Google Patents

Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere

Info

Publication number
NO20055774L
NO20055774L NO20055774A NO20055774A NO20055774L NO 20055774 L NO20055774 L NO 20055774L NO 20055774 A NO20055774 A NO 20055774A NO 20055774 A NO20055774 A NO 20055774A NO 20055774 L NO20055774 L NO 20055774L
Authority
NO
Norway
Prior art keywords
protein formulations
pharmaceutical containers
coated pharmaceutical
stabilized protein
liquid stabilized
Prior art date
Application number
NO20055774A
Other languages
English (en)
Other versions
NO20055774D0 (no
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33442722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055774(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20055774L publication Critical patent/NO20055774L/no
Publication of NO20055774D0 publication Critical patent/NO20055774D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Det er beskrevet en beholder som omfatter en lukkeanordning belagt med et inert fluorinert materiale som inneholder en flytende farmasøytisk sammensetning. Særhg omfatter beholderen en lukkeanordning belagt med TEFLON og som inneholder en HSA-fri interferon-beta-formulering som har følgende sammensetning: 30-100 mikrogram/ml av interferon-beta, et isotonisitetsmiddel, 0,1-2 mg/ml av Poloxamer 188, minst 0,12 mg/ml av L-metionin og en bufferoppløsning som er i stand til å opprettholde pH i den flytende formuleringen på en verdi mellom 3,0 og 4,0.
NO20055774A 2003-05-13 2005-12-06 Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere NO20055774D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010671 2003-05-13
PCT/EP2004/050779 WO2004100979A2 (en) 2003-05-13 2004-05-12 Liquid stabilized protein formulations in coated pharmaceutical containers

Publications (2)

Publication Number Publication Date
NO20055774L true NO20055774L (no) 2005-12-06
NO20055774D0 NO20055774D0 (no) 2005-12-06

Family

ID=33442722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055774A NO20055774D0 (no) 2003-05-13 2005-12-06 Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere

Country Status (22)

Country Link
US (2) USRE43331E1 (no)
EP (2) EP1633388B1 (no)
JP (2) JP2007502684A (no)
KR (1) KR101084412B1 (no)
CN (1) CN1809376B (no)
AR (1) AR044302A1 (no)
AU (1) AU2004237982C1 (no)
BR (1) BRPI0410679A (no)
CA (1) CA2523477A1 (no)
CY (1) CY1115233T1 (no)
DK (1) DK1633388T3 (no)
EA (1) EA008308B1 (no)
ES (1) ES2471942T3 (no)
HR (1) HRP20140267T1 (no)
IL (1) IL171912A (no)
MX (1) MXPA05012191A (no)
NO (1) NO20055774D0 (no)
PL (1) PL1633388T3 (no)
PT (1) PT1633388E (no)
SI (1) SI1633388T1 (no)
UA (1) UA91493C2 (no)
WO (1) WO2004100979A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070012464A (ko) * 2004-05-17 2007-01-25 아레스 트레이딩 에스.아. 하이드로겔 인터페론 제제
MXPA06014078A (es) * 2004-06-01 2007-02-15 Ares Trading Sa Formulaciones liquidas estabilizadas de interferon.
ES2588583T3 (es) * 2005-01-12 2016-11-03 Biogen Ma Inc. Procedimiento para suministrar interferón beta
EP1909838A2 (en) * 2005-07-29 2008-04-16 Amgen Inc. Formulations that inhibit protein aggregation
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
KR100785070B1 (ko) 2006-07-11 2007-12-12 삼성전자주식회사 휴대 단말기에서 디지털 저작권 관리 콘텐츠 재생 방법 및장치
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US9138403B2 (en) * 2007-12-20 2015-09-22 Merck Serono Sa PEG-interferon-beta formulations
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
TW202012427A (zh) 2012-12-03 2020-04-01 美商諾維生物製藥有限公司 新穎縮肽及其用途
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
EP3613423B1 (en) 2013-07-10 2022-10-26 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
BR112016010475B1 (pt) * 2014-03-13 2021-07-20 Stevanato Group International A.S. Método de manuseio de uma formulação farmacêutica líquida
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN108135926A (zh) 2015-09-24 2018-06-08 基质生物研究所 高弹性透明质酸组合物及其使用方法
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
US11203616B2 (en) 2017-04-04 2021-12-21 Novobiotic Pharmaceuticals, Llc Depsipeptides and uses thereof
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
JP2024500994A (ja) 2020-12-28 2024-01-10 デボル，インコーポレイテッド タンパク質及び多官能化変性ポリエチレングリコール系架橋剤を含む反応性乾燥粉末状止血用材料

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2622598A (en) * 1951-03-08 1952-12-23 Premo Pharmaceutical Lab Inc Drain-clear container for aqueous liquid pharmaceutical preparations
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
EP0639114B1 (en) 1992-05-06 2000-08-09 Mallinckrodt Inc. Container and closure system for maintaining stability of sodium hypochlorite solutions
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW249202B (no) 1993-08-13 1995-06-11 Ciba Gerigy Corp
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
WO1997017087A1 (en) * 1995-11-07 1997-05-15 Genentech, Inc. Stabilizing formulation for ngf
US6142977A (en) 1996-10-18 2000-11-07 Schering Ag Prefilled, sterilized syringe with a new and improved plug
PT948358E (pt) * 1996-12-24 2004-10-29 Biogen Idec Inc Formulacoes de interferao liquidas e estaveis
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CN2326243Y (zh) 1997-09-29 1999-06-30 程继勇 覆膜药用瓶塞
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CN2441750Y (zh) * 2000-06-23 2001-08-08 程继勇 表面覆膜药用橡胶瓶塞
JP2002209975A (ja) * 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CN1133565C (zh) * 2001-10-18 2004-01-07 郑秀娣 药品瓶塞隔离膜

Also Published As

Publication number Publication date
IL171912A (en) 2015-02-26
EP1633388B1 (en) 2014-03-19
HRP20140267T1 (hr) 2014-04-25
PT1633388E (pt) 2014-06-25
USRE43331E1 (en) 2012-05-01
KR101084412B1 (ko) 2011-11-21
CY1115233T1 (el) 2017-01-04
WO2004100979A3 (en) 2005-05-19
HK1088558A1 (zh) 2006-11-10
AR044302A1 (es) 2005-09-07
JP2012096063A (ja) 2012-05-24
BRPI0410679A (pt) 2006-06-20
PL1633388T3 (pl) 2014-08-29
US20070092487A1 (en) 2007-04-26
AU2004237982B2 (en) 2010-03-04
MXPA05012191A (es) 2006-02-08
US7540382B2 (en) 2009-06-02
CN1809376B (zh) 2010-04-28
EP1633388A2 (en) 2006-03-15
EA008308B1 (ru) 2007-04-27
WO2004100979A2 (en) 2004-11-25
CN1809376A (zh) 2006-07-26
EP2324845A1 (en) 2011-05-25
DK1633388T3 (da) 2014-04-07
SI1633388T1 (sl) 2014-05-30
UA91493C2 (uk) 2010-08-10
JP2007502684A (ja) 2007-02-15
CA2523477A1 (en) 2004-11-25
AU2004237982C1 (en) 2018-03-08
EA200501692A1 (ru) 2006-06-30
KR20060009913A (ko) 2006-02-01
IL171912A0 (en) 2006-04-10
ES2471942T3 (es) 2014-06-27
NO20055774D0 (no) 2005-12-06
AU2004237982A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
NO20055774L (no) Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
AR092919A2 (es) Composicion farmaceutica liquida
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
BRPI0410488A (pt) composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa'
JP2007502684A5 (no)
NZ505324A (en) Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
NZ294464A (en) Stable, aqueous formulation having high biological alpha-type interferon activity buffered from 4.5 to 7.1 and comprising chelating agent and a polyoxyethylene sorbitan monooleate, formulation free from human blood-derived products
CY1112193T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης
MY136136A (en) Pharmaceutical compositions containing terbinafin and use thereof
ATE252376T1 (de) Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln
NO20065860L (no) Stabiliserte flytende interferonformuleringer
IL165322A0 (en) Pharmaceutical preparations for oral administration containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
AR034749A1 (es) Formulaciones de interferon beta humano
AR037131A1 (es) Formulaciones de jarabe de ribavirina
Arita et al. Sesiidae of Taiwan II. The tribes Osminiini, Melittiini and Sesiini
NO20004816L (no) Ny farmasøytisk formulering
BR0111018A (pt) Formulações estáveis lìquidas e sólidas
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
AU774560B2 (en) Storage container for weakly acidic solution formulation containing human growth hormone, injection cartridge therefor and storage method therefor
JPH09164180A (ja) 液剤の容器
Shah et al. Long-acting microbicide delivery system

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application